Lyra Therapeutics Withdraws Appeal Of Nasdaq Delisting Determination; Trading In Co's Common Stock To Be Suspended At Open On March 17, 2026

Lyra Therapeutics, Inc. has withdrawn its appeal against a delisting determination from Nasdaq, which was issued on February 2, 2026. As a result, trading of the company's common stock (LYRA) will be suspended at the open on March 17, 2026. Nasdaq will also file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission following the completion of internal procedural periods.